Irbesartan Generis (Irbesartan)

Irbesartan blocks the angiotensin II type‑1 (AT1) receptors, preventing angiotensin II from causing blood‑vessel constriction and aldosterone release. This results in vasodilation, reduced sodium‑water retention, and lower systemic blood pressure.

The exact dose of Irbesartan Generis is determined by the prescribing clinician based on the individual’s blood‑pressure goals, kidney function, and other medical factors. Dosage adjustments are made according to the patient’s response and tolerability.

Irbesartan is contraindicated in pregnancy because it can cause fetal harm, especially in the second and third trimesters. Limited data are available for breastfeeding; therefore, it is generally avoided unless the benefit clearly outweighs the risk.

To request Irbesartan Generis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly on vascular smooth‑muscle calcium channels.

Irbesartan Generis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Irbesartan Generis is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include angioedema, severe hypotension, acute kidney injury, and dangerous elevations in serum potassium (hyperkalemia). Patients should seek immediate medical attention if they experience swelling of the face or throat, faintness, rapid heartbeat, or significant changes in urine output.

Irbesartan Generis should not be used by individuals who are pregnant, have known hypersensitivity to irbesartan or any ARB, or have severe hepatic impairment. Caution is also advised for patients with bilateral renal artery stenosis or those on concurrent potassium‑raising therapies.